 Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 1 | 3 | | 2011 | 5 | 10 | 15 | | 2012 | 7 | 5 | 12 | | 2013 | 14 | 9 | 23 | | 2014 | 13 | 15 | 28 | | 2015 | 9 | 18 | 27 | | 2016 | 9 | 18 | 27 | | 2017 | 5 | 23 | 28 | | 2018 | 10 | 20 | 30 | | 2019 | 5 | 22 | 27 | | 2020 | 2 | 11 | 13 | | 2021 | 4 | 6 | 10 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 12 | 13 | | 2025 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
Secord AA, Bae-Jump V, Backes F, Thaker P, Gehrig PA, Previs RA, Borden L, Thomas SM, Jackson A, Konecny GE, Duska LR, Arend R, Wright J, Corr B, Maxwell GL, Cosgrove CM, Mullen MM, Washington C, Herzog TJ, Cohen J, Hou J, Gaillard S, Fader AN, Berchuck A, Pothuri B. Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Int J Gynecol Cancer. 2025 May; 35(5):101758.
-
Andrysik Z, Espinosa JM. Harnessing p53 for targeted cancer therapy: new advances and future directions. Transcription. 2025 Feb; 16(1):3-46.
-
Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer. Cells. 2025 02 20; 14(5).
-
Theocharopoulos C, Ziogas IA, Mungo B, Gogas H, Ziogas DC, Kontis E. HER2-targeted therapies: Unraveling their role in biliary tract cancers. Crit Rev Oncol Hematol. 2025 Apr; 208:104655.
-
Decoster L, Camidge DR, Fletcher JA, Addeo A, Greystoke A, Kantilal K, Game LB, Kanesvaran R, Gomes F. Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group. Lung Cancer. 2025 Feb; 200:108087.
-
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Reddy NK, Subbiah V. Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. 2024 Nov 11; 42(11):1970-1982.e7.
-
Saeedi BJ, Carr HE, Higgins PDR, Steiner CA. AXL: A novel therapeutic target in IBD. Adv Pharmacol. 2024; 101:141-157.
-
Dickinson K, Yee EJ, Vigil I, Schulick RD, Zhu Y. GPCRs: emerging targets for novel T cell immune checkpoint therapy. Cancer Immunol Immunother. 2024 Oct 03; 73(12):253.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|